AC Immune SA announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika B?tler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. B?tler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM. Monica Shaw, M.D., is a pharmaceutical industry expert who has held senior leadership positions and was involved in advancing more than 15 therapeutic products from first-in-human studies through regulatory approvals and commercialization across multiple geographies. She also played key business development roles in company acquisition and integration and co-development partnerships. Through her work, Dr. Shaw gained extensive specialty experience in the fields of dermatology, immuno-inflammation, HIV, neurology, and oncology. Currently, Dr. Shaw is Executive Vice President Head Region Europe, Canada, Australia, for Leo Pharma. She has previously held broad leadership roles at other leading pharmaceutical companies, including as Vice President Commercial Head Asia Pacific region at GSK/ViiV Healthcare, and Medical Director and Chief Scientific Officer UK for Novartis, in addition to previous leadership positions at Norgine, Shire and Merck KGaA. Prof. Monika B?tler, Dr. oec., is a leading Swiss economist and former Vice President of the independent Swiss COVID-19 Science Taskforce. She is a member of the Board of Directors and the audit committees of both Schindler Holding AG and Huber & Suhner AG. Prof. B?tler is also a member of the Swiss National Bank?s Council, where she serves on the remuneration committee. Her international economic expertise is in public policy and managerial economics, including an advisory role to the World Bank and work in the U.S. and Europe. Prof. B?tler is a Vice President of the Foundation Board of the Gebert R?f Foundation, a science and innovation foundation that supports entrepreneurial projects which are committed to achieving an impact.